Home

Executives

Acquisitions/Mergers

Funding

FDA Updates

Clinical Trials

Medical Device News

DCN Dx Acquires Microbiological Testing Products Company Biomed Diagnostics

Latest Posts

Abraham Verghese MD Appointed to the Board of Directors of Athos Therapeutics

"Abraham Verghese MD is a highly distinguished physician, humanist, administrator, and adviser," said Allan Pantuck, MD, MS, FACS, Chairman & CMO.

University of Nebraska Medical Center and ANANDA Scientific announce FDA approval of the IND for a Clinical Trial exploring Treatment for Post-Traumatic Stress Disorder

The study will evaluate the effectiveness of Nantheia™ ATL5, an investigational drug-using cannabidiol in ANANDA’s proprietary delivery technology. An investigational new drug (IND) application for the trial has been approved by the FDA.

BRIM Biotechnology & Ora Announce New Partnership

BRIM Biotechnolgy notes the new partnership builds on the success of our previous collaboration for Phase 2 trials and will help to speed the progression of BRM421 through late-stage clinical development toward regulatory filing.

Cytel Designed & Led TOGETHER Trial Wins Society of Clinical Trial’s David Sackett Trial of the Year Award

TOGETHER trial has enrolled over 6000 patients in 22 research sites in Brazil.  It is now expanding to Pakistan and South Africa, Rwanda, DRC, and Vietnam.

DCN Dx, a global leader in the end-to-end development, manufacture, and commercialization of point-of-use tests, today announced it has completed its acquisition of Biomed Diagnostics, Inc., a microbiological testing products company based in White City, Oregon.

Biomed has an established history of developing tools for the surveillance of microorganisms that lead to infectious diseases in humans and animals. Originally developed for use in low-resource settings, these tools are now recognized around the world for their utility, ease of use, and accuracy.

“Biomed has a strong presence in microbiological testing for veterinary, human, food safety and environmental markets, and has developed innovative solutions that combine specimen collection, culture and transport in a single device,” said Charlie Mamrak, DCN Dx’s CEO. “The portfolio of novel testing and sampling products is a perfect adjacency for DCN Dx’s core business of point-of-use test development. We’re excited to integrate Biomed’s capabilities into our own as we provide world-class solutions to our clients.”

New Products

Biomed brings a number of products to DCN Dx’s stable, including:

  • InPouch TF®, a simple-to-use culture media for the detection of the parasite that causes bovine trichomoniasis
  • TF Transit Tube, a self-contained system for the collection and transport of Tritrichomonas foetus from bovine preputial or vaginal samples
  • InPouch® TV, a self-contained broth media device for the recovery and detection of Trichnomonas vaginalis from human female vaginal samples or male urethra/urine samples
  • Transport Media (VTM) for SARS-CoV-2 sample transport
  • The INTRAY® VS COLOREXTM product line for convenient testing for microbes including MRSA and other resistant bacteria

About DCN Dx
CN Dx is a global leader in the end-to-end development, manufacture, and commercialization of point-of-use tests. From its headquarters in Carlsbad, California, DCN Dx’s cross-functional team of scientists and engineers develop and integrate all aspects of assays into reliable systems for point-of-use applications that enable users to monitor sample quality, identify pathogens, and facilitate the delivery of treatments. DCN Dx partners with industry leaders to develop point-of-use tests, train users in diagnostic development, and carry out clinical research for medical point-of-care testing, veterinary diagnostics, soil and water testing, bioprocessing, food safety, force protection, and more.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine